SCPH News & Events

MannKind Corporation completed the previously announced acquisition of scPharmaceuticals. The acquisition of scPharmaceuticals is expected to diversify and accelerate MannKind's double-digit revenue growth, driven by FUROSCIX an innovative therapy for edema due to chronic heart failure and chronic kidney disease. The transaction will strengthen MannKind's commercial and medical capabilities by integrating scPharmaceuticals' experienced team into its existing infrastructure. MannKind is positioned as a diversified, growth-focused biopharmaceutical company with its commercial assets-Afrezza, FUROSCIX and V-Go -- along with Tyvaso DPI(R)-related revenues, contributing to an annualized run rate of over $370 million based on Q2 2025 results. Additionally, the FUROSCIX ReadyFlow Autoinjector supplemental New Drug Application filing was submitted as planned in Q3 2025. The acquisition was structured as a tender offer to acquire all of the outstanding shares of scPharmaceuticals common stock at a price of $5.35 per share in cash plus one non-tradable contingent value right per share to receive certain milestone payments of up to an aggregate of $1.00 per CVR in cash, for total consideration of up to $6.35 per share in cash. The non-tradable CVR is payable upon achieving certain regulatory and net sales milestones.

H.C. Wainwright downgraded scPharmaceuticals (SCPH) to Neutral from Buy with a price target of $5.35, down from $18, after the company agreed to be acquired by MannKind (MNKD) for $5.35 per share in cash plus one non-tradable contingent value right per share to receive certain milestone payments of up to an aggregate of $1.00.